• OPEN AN ACCOUNT
Indian Indices
Nifty
25,083.75 33.20
(0.13%)
Sensex
82,000.71 142.87
( 0.17%)
Bank Nifty
55,755.45 56.95
( 0.10%)
Nifty IT
35,723.90 33.85
( 0.09%)
Global Indices
Nasdaq
44,950.40 7.12
(0.02%)
Dow Jones
6,415.95 -16.42
(-0.26%)
Hang Seng
42,650.99 -237.56
(-0.55%)
Nikkei 225
9,288.14 98.92
(1.08%)
Forex
USD-INR
87.11 -0.26
(-0.30%)
EUR-INR
101.58 -0.47
(-0.46%)
GBP-INR
117.61 -0.63
(-0.53%)
JPY-INR
0.59 0.00
(-0.35%)

EQUITY - MARKET SCREENER

Fredun Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
539730
INE194R01017
299.4743419
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
21.29
499.1
EPS(TTM)
Face Value()
Div & Yield %
49.65
10
0.07
 

BFL Asset Finvest Ltd - Board Meeting Intimation for Approving The Un-Audited Financial Results Of The Company For The Quarter Ended On June 2025 And Other Matters.
Jul 21,2025
BFL Asset Finvest Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2025 inter alia to consider and approve 1. the Un-audited Financial Results of the Company for the Quarter ended on June 30 2025 pursuant to Regulation 33 of the Listing Regulations and to take on record the Limited Review Report thereon. 2. Re-appointment of Mr. Mahendra Kumar Baid as Managing Director of the company for a further period of 3 (three) years commencing from July 28 2026 to July 27 2029 subject to approval of shareholders in the ensuing Annual General Meeting. 3. Appointment of M/s ABSM & Associates (FRN: 015966C) Chartered Accountants as the Statutory Auditor of the Company for the term of 5 (five) consecutive years commencing from FY 2025-26 to FY 2029-30 subject to approval of members in the ensuing Annual General Meeting.